Ultrasonography has proven useful for diagnosis and treatment monitoring in patients with hidradenitis sup-purativa. The aim of this study was to assess the clinical response to adalimumab using ultrasound findings. This prospective study collected data on demographic features, disease severity, and hidradenitis suppura-tiva findings from patients with hidradenitis suppura-tiva treated with adalimumab. Generalized estimating equations investigated relationships between disease severity measures and clinical/demographic variables. The study included a total of 41 patients with hidra-denitis suppurativa who were treated with adalimu-mab for a mean ± SD period of 50.8 ± 32.2 weeks; range 6–108 weeks). Clinical improvement was observed during adalimumab therapy, with a progressively greater number of patients achieving HiSCR50 response (36.4% at week 52). Disease duration was identified as the most relevant clinical variable affecting disease severity and treatment response. Treatment response was also influenced by treatment duration, with a 4% greater likelihood of achieving HiSCR50 response at each time-point. At the ultrasound examination, sub-cutaneous involvement of hidradenitis suppurativa lesions was identified as a predictive negative factor for clinical response to adalimumab (HiSCR50 achie-vement).

Chiricozzi, A., Giovanardi, G., Garcovich, S., Malvaso, D., Caldarola, G., Fossati, B., Guerriero, C., De Simone, C., Peris, K., Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience, <<ACTA DERMATO-VENEREOLOGICA>>, 2020; (13): 1-6. [doi:10.2340/00015555-3520] [http://hdl.handle.net/10807/168887]

Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience

Chiricozzi A.;Garcovich S.;Malvaso D.;Caldarola G.;Fossati B.;Guerriero C.;DE SIMONE C.;Peris K.
2020

Abstract

Ultrasonography has proven useful for diagnosis and treatment monitoring in patients with hidradenitis sup-purativa. The aim of this study was to assess the clinical response to adalimumab using ultrasound findings. This prospective study collected data on demographic features, disease severity, and hidradenitis suppura-tiva findings from patients with hidradenitis suppura-tiva treated with adalimumab. Generalized estimating equations investigated relationships between disease severity measures and clinical/demographic variables. The study included a total of 41 patients with hidra-denitis suppurativa who were treated with adalimu-mab for a mean ± SD period of 50.8 ± 32.2 weeks; range 6–108 weeks). Clinical improvement was observed during adalimumab therapy, with a progressively greater number of patients achieving HiSCR50 response (36.4% at week 52). Disease duration was identified as the most relevant clinical variable affecting disease severity and treatment response. Treatment response was also influenced by treatment duration, with a 4% greater likelihood of achieving HiSCR50 response at each time-point. At the ultrasound examination, sub-cutaneous involvement of hidradenitis suppurativa lesions was identified as a predictive negative factor for clinical response to adalimumab (HiSCR50 achie-vement).
Inglese
Chiricozzi, A., Giovanardi, G., Garcovich, S., Malvaso, D., Caldarola, G., Fossati, B., Guerriero, C., De Simone, C., Peris, K., Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience, <>, 2020; (13): 1-6. [doi:10.2340/00015555-3520] [http://hdl.handle.net/10807/168887]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/168887
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact